Evidence map›Paper›PMID 39062100›Full record

ReviewBiomedicines2024

Osteopontin: A Key Multifaceted Regulator in Tumor Progression and Immunomodulation.

Venketesh K Panda, Barnalee Mishra, Angitha N Nath, Ramesh Butti, Amit Singh Yadav, Diksha Malhotra, Sinjan Khanra, Samikshya Mahapatra, Priyanka Mishra, Biswajit Swain and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. SPP1Cell death & disease · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Venketesh K PandaSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.ORCID 0000-0002-6633-2898
Barnalee MishraSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.
Angitha N NathSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.
Ramesh ButtiDivision of Hematology and Oncology, Department of Internal Medicine, Southwestern Medical Center, University of Texas, Dallas, TX 75235, USA.
Amit Singh YadavBiomedical Centre, Faculty of Medicine, Lund University, 223 62 Lund, Sweden.ORCID 0000-0002-5118-4538
Diksha MalhotraSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.
Sinjan KhanraSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.ORCID 0009-0006-7117-1730
Samikshya MahapatraSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.
Priyanka MishraSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.
Biswajit SwainSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.
Sambhunath MajhiSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.
Kavita KumariSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.
N N V RadharaniBiomedical Centre, Faculty of Medicine, Lund University, 223 62 Lund, Sweden.
Gopal C KunduSchool of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.

Funding

Department of Biotechnology (DBT), Govt of India BT/PR-32388/TRM/120/242/2019DST INSPIRE Fellowship Program, Govt. of India DST INSPIRE /2021/IF210059Science and Engineering Research Board (SERB), Govt. of India JCB/2023/000011
6 · The paper itself

Abstract

The tumor microenvironment (TME) is composed of various cellular components such as tumor cells, stromal cells including fibroblasts, adipocytes, mast cells, lymphatic vascular cells and infiltrating immune cells, macrophages, dendritic cells and lymphocytes. The intricate interplay between these cells influences tumor growth, metastasis and therapy failure. Significant advancements in breast cancer therapy have resulted in a substantial decrease in mortality. However, existing cancer treatments frequently result in toxicity and nonspecific side effects. Therefore, improving targeted drug delivery and increasing the efficacy of drugs is crucial for enhancing treatment outcome and reducing the burden of toxicity. In this review, we have provided an overview of how tumor and stroma-derived osteopontin (OPN) plays a key role in regulating the oncogenic potential of various cancers including breast. Next, we dissected the signaling network by which OPN regulates tumor progression through interaction with selective integrins and CD44 receptors. This review addresses the latest advancements in the roles of splice variants of OPN in cancer progression and OPN-mediated tumor-stromal interaction, EMT, CSC enhancement, immunomodulation, metastasis, chemoresistance and metabolic reprogramming, and further suggests that OPN might be a potential therapeutic target and prognostic biomarker for the evolving landscape of cancer management.

Indexed as

cancercancer-associated fibroblastsimmunomodulationosteopontin (OPN)single cell transcriptomicstargeted therapytumor-associated macrophages

Identifiers

PMID39062100
PMCPMC11274826

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.